Genomic Instability
Recent clinical, regulatory, research and industry developments relating to this disease.
Genomic instability as a driver and suppressor of anti-tumor immunity.
Decoding p53 tumor suppression: a crosstalk between genomic stability and epigenetic control?
Genomic consequences associated with Agrobacterium-mediated transformation of plants.
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments.
Human topoisomerases and their roles in genome stability and organization.
G-quadruplexes: a promising target for cancer therapy.
PARP and PARG inhibitors in cancer treatment.
Measuring biological aging in humans: A quest.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Ovarian cancer Lynparza is indicated as monotherapy for the: maintenance treatment of ad… (2014)
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Genomic Instability4
- Neoplasms4
- Epigenesis, Genetic2
- DNA Damage1
- DNA Repair1
- DNA, Neoplasm1
- Health Promotion1
- Molecular Targeted Therapy1
Leading journals6
- Signal transduction and targeted therapy2
- Aging cell1
- Cell death and differentiation1
- Frontiers in immunology1
- Genes & development1
- Molecular cancer1
Leading researchers8
- Abad E1
- Amelio I1
- Austin C1
- Brossart P1
- de Bruyn M1
- de Cabo R1
- Dickinson L1
- Dou L1
Affiliations (unnormalised)6
- Beijing Key Laboratory for Radiobiology1
- Biomedical Research Center1
- Biosciences Institute1
- European Research Institute for the Biology of Ageing1
- Laboratory of Genomic Integrity1
- Laboratory of Molecular Pharmacology1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Genomic instability is an increased tendency of the genome to acquire mutations when processes that maintain and replicate the genome are dysfunctional. It is discussed in the literature as a hallmark of cancer and as one of the endogenous stresses linked to aging and aging-related disease.
The supplied grounding supports dysfunctional genome maintenance and replication processes as the basis of genomic instability. It is also associated with endogenous and exogenous stresses, including oxidative and replication stress, DNA damage, and defects in DNA repair.
Genomic instability arises when DNA damage accumulates or when DNA repair and replication fidelity are compromised. The literature also links it to epigenetic alterations, cellular senescence, aging, and altered genome organization, including topoisomerase-related DNA breaks and G-quadruplex-associated mutations, deletions, and recombination events.
Supported risk factors or associated contexts include aging, cellular senescence, oxidative stress, replication stress, and defects in DNA damage repair pathways. It is also associated with cancer and with conditions in which genome maintenance is impaired.
There is no disease-specific standard treatment described in the grounding. In cancer, genomic instability is exploited therapeutically through radiotherapy and chemotherapy, and through targeted cancer therapy that suppresses DNA damage response pathways, including PARP inhibitors in tumors with DNA repair gene mutations.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
An increased tendency of the GENOME to acquire MUTATIONS when various processes involved in maintaining and replicating the genome are dysfunctional.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.